ArticlesCetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Introduction
Patients with advanced non-small-cell lung cancer are treated with a combination of a platinum drug (cisplatin or carboplatin) and a non-platinum drug (eg, vinorelbine), which results in a slight increase in survival and relief of cancer-related symptoms.1 Cisplatin-based two-drug combinations are slightly better than carboplatin-based combinations in patients with good performance status and adequate organ function.2 Strategies to further improve survival of patients with advanced non-small-cell lung cancer include the addition of targeted drugs to cytotoxic chemotherapy,3 and chemotherapy that is customised according to biomarkers.4
Epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small-cell lung cancer.5 The EGFR-directed tyrosine kinase inhibitors erlotinib and gefitinib are established treatment options for patients with advanced disease who have been pretreated with platinum-based combinations6, 7 but their addition to first-line chemotherapy does not improve outcome.8, 9, 10, 11 Cetuximab (Erbitux, developed by Merck KGaA, Darmstadt, Germany, under licence from Imclone Systems, Branchburg, NJ, USA), an anti-EGFR immunoglobulin G1 monoclonal antibody, has shown activity when given in combination with cisplatin in preclinical studies.12, 13 The results of a randomised phase II trial in 86 patients with advanced EGFR-expressing non-small-cell lung cancer suggested an increased response rate and improved survival in patients given cisplatin and vinorelbine plus cetuximab compared with those given the same chemotherapy alone.14 We therefore did the phase III FLEX (First-Line ErbituX in lung cancer) trial with the aim of showing a prolonged overall survival time with chemotherapy plus cetuximab compared with chemotherapy alone as first-line treatment in patients with EGFR-expressing advanced non-small-cell lung cancer.
Section snippets
Study design
We randomly assigned chemotherapy-naive patients with EGFR-expressing advanced non-small-cell lung cancer centrally using an interactive voice response system (IVRS) in a ratio of 1:1 to chemotherapy plus cetuximab or chemotherapy alone in a multinational, open-label, phase III trial done in 155 centres. The clinical research organisation generated the random allocation schedule using a computer; physicians and study monitors did not have access to the code. Randomisation was stratified by the
Results
Figure 1 shows the trial profile. Between October, 2004, and January, 2006, 1125 patients (intention-to-treat population) were assigned to chemotherapy plus cetuximab or just chemotherapy. Table 1 shows that the baseline characteristics of the randomly assigned patients were well balanced between the groups.
Median number of chemotherapy cycles given to patients was four (range 0–6 for chemotherapy plus cetuximab, and 1–7 for chemotherapy alone) and median duration of chemotherapy was 14 weeks
Discussion
The FLEX trial showed that overall survival is prolonged with the EGFR targeted antibody cetuximab added to chemotherapy in patients with advanced non-small-cell lung cancer across all histological subtypes. Results of this study are consistent with those from other randomised phase II trials14, 15, 16 and the BMS-099 phase III trial.17, 18 The BMS-099 trial17, 18 was not powered to detect a significant difference in overall survival. However, a reduction in the risk of death of the same
References (28)
- et al.
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Lancet
(2008) - et al.
Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells
J Biol Chem
(1994) - et al.
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Ann Oncol
(2008) - et al.
A randomized multicenter phase III study of cetuximab in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
J Thorac Oncol
(2007) - et al.
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003
J Clin Oncol
(2004) - et al.
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
J Natl Cancer Inst
(2007) - et al.
New molecularly targeted therapies for lung cancer
J Clin Invest
(2007) - et al.
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer
J Clin Oncol
(2007) Targeting the epidermal growth factor receptor for cancer therapy
J Clin Oncol
(2002)- et al.
Erlotinib in previously treated non-small-cell lung cancer
N Engl J Med
(2005)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1
J Clin Oncol
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2
J Clin Oncol
TRIBUTE: a phase III trial of Erlotinib Hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
J Clin Oncol
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
J Clin Oncol
Cited by (1277)
Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review
2023, International Journal of Biological MacromoleculesLigand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers
2023, Molecular Therapy Oncolytics
- ‡
Members listed at the end of the paper